AZ gets closer to Ionis, licensing amyloidosis drug in $3.6bn dealAstraZeneca has snapped up another Ionis-discovered drug for its pipeline, this time phase 3 candidate eplontersen for the Share XAZ gets closer to Ionis, licensing amyloidosis drug in $3.6bn dealhttps://pharmaphorum.com/news/az-gets-closer-to-ionis-licensing-amyloidosis-drug-in-3-6bn-deal/
Merck halts more trials of HIV candidate islatravirMerck & Co has halted enrolment in a pair of phase 3 trials of its experimental HIV drug Share XMerck halts more trials of HIV candidate islatravirhttps://pharmaphorum.com/news/merck-halts-more-trials-of-hiv-candidate-islatravir/
Viagra ‘should be tested as Alzheimer’s therapy’Scientists in the US have found that people who use Viagra for erectile dysfunction seem to have a Share XViagra ‘should be tested as Alzheimer’s therapy’https://pharmaphorum.com/news/viagra-should-be-tested-as-alzheimers-therapy/
Novartis takes aim at risky Parkinson’s target with $1.5bn UCB dealNovartis has licensed a potential drug for Parkinson’s from Belgium’s UCB that it thinks could be the first Share XNovartis takes aim at risky Parkinson’s target with $1.5bn UCB dealhttps://pharmaphorum.com/news/novartis-takes-aim-at-risky-parkinsons-target-with-1-5bn-ucb-deal/
GSK pumps £30m into a new Oxford University partnershipGlaxoSmithKline has formed a five-year partnership with Oxford University to set up a new institute that will apply Share XGSK pumps £30m into a new Oxford University partnershiphttps://pharmaphorum.com/news/gsk-pumps-30m-into-a-new-oxford-university-institute/
Dyno attracts $1.6bn gene therapy deal with AstellasAstellas has signed another bolt-on deal to build its gene therapy pipeline, agreeing a deal with Dyno Therapeutics Share XDyno attracts $1.6bn gene therapy deal with Astellashttps://pharmaphorum.com/news/dyno-attracts-1-6bn-gene-therapy-deal-with-astellas/
Sanofi snaps up acne vaccine developer Origimm BioSanofi has added to its vaccine pipeline with an agreement to acquire Austria’s Origimm Biotechnology and its vaccine-based Share XSanofi snaps up acne vaccine developer Origimm Biohttps://pharmaphorum.com/news/sanofi-snaps-up-acne-vaccine-developer-origimm-bio/
GSK poaches Pfizer exec Dormitzer as new vaccines R&D chiefGlaxoSmithKline has found a replacement for head of vaccines R&D Emmanuel Hanon, who left the company for a Share XGSK poaches Pfizer exec Dormitzer as new vaccines R&D chiefhttps://pharmaphorum.com/news/gsk-poaches-pfizer-exec-dormitzer-as-new-vaccines-chief/
Report suggests UK’s national vaccine facility is on the blockThe UK’s Vaccines Manufacturing and Innovation Centre (VMIC) – unveiled with fanfare by the government in 2018 – Share XReport suggests UK’s national vaccine facility is on the blockhttps://pharmaphorum.com/news/report-suggests-uks-national-vaccine-facility-is-on-the-block/
